Vimarsana
Biggest News Aggregation in the World

Page 3 - New Technologies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from New Technologies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In New Technologies Today - Breaking & Trending Today

Genmab A/S : Investigational Acasunlimab (DuoBody® PD L1x4 1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non small Cell Lung Cancer (mNSCLC) - Vimarsana News

Genmab A/S : Investigational Acasunlimab (DuoBody® PD L1x4 1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non small Cell Lung Cancer (mNSCLC)

Published: June 1, 2024

English ...

Source: marketscreener.com
Related Topics:
United StatesAndrew CarlsenAcasunlimab DuobodyAsia PacificFosun PharmaDavid FreundelRoche GroupGlobal Communications Corporate AffairsExchange CommissionAmerican Society Of Clinical OncologyAmerican Cancer SocietyClinical OncologyAnnual MeetingNon Small Cell Lung CancerNorth AmericaMedia ReleaseAnnual ReportY Shaped GenmabNew TechnologiesPrivate Securities Litigation Reform ActSenior DirectorGlobal CommunicationsVice PresidentAmerican CancerNon Small Cell Lung
BioNTech SE: Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) - Vimarsana News

BioNTech SE: Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Published: June 1, 2024

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic non-small

Source: finanznachrichten.de
Related Topics:
United StatesDavid FreundelFosun PharmaAndrew CarlsenJudith KlimovskyAmerican Society Of Clinical OncologyExchange CommissionRoche GroupAmerican Cancer SocietyClinical OncologyAnnual MeetingExecutive Vice PresidentChief Development OfficerChief Medical OfficerNon Small Cell Lung CancerMedia ReleaseAnnual ReportY Shaped GenmabNew TechnologiesPrivate Securities Litigation Reform ActAmerican CancerNon Small Cell LungLung CancerSmall CellIhr Portfolio
Genmab A/S: Investigational Acasunlimab (DuoBody -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) - Vimarsana News

Genmab A/S: Investigational Acasunlimab (DuoBody -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Published: June 1, 2024

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival (mOS) of 17.5 months in patients with previously treated PD-L1-positive

Source: finanznachrichten.de
Related Topics:
United StatesAsia PacificDavid FreundelFosun PharmaAndrew CarlsenAmerican Society Of Clinical OncologyRoche GroupExchange CommissionGlobal Communications Corporate AffairsAmerican Cancer SocietyClinical OncologyAnnual MeetingNon Small Cell Lung CancerNorth AmericaMedia ReleaseAnnual ReportY Shaped GenmabNew TechnologiesPrivate Securities Litigation Reform ActAmerican CancerNon Small Cell LungAccessed MayLung Cancer Non Small CellSenior DirectorVice President
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab ... - Vimarsana News

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab ...

Published: June 1, 2024

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive

Source: bdtonline.com
Related Topics:
United StatesAsia PacificAndrew CarlsenFosun PharmaDavid FreundelExchange CommissionRoche GroupAmerican Cancer SocietyAmerican Society Of Clinical OncologyClinical OncologyAnnual MeetingNon Small Cell Lung CancerNorth AmericaMedia ReleaseAnnual ReportY Shaped GenmabNew TechnologiesPrivate Securities Litigation Reform ActAmerican CancerNon Small Cell LungAccessed MayLung CancerNon Small Cell
Forum of Kazakh-Language Content Creators in Astana Explores Emerging Trends and Risks - Vimarsana News

Forum of Kazakh-Language Content Creators in Astana Explores Emerging Trends and Risks

Published: May 31, 2024

Forum of Kazakh-Language Content Creators in Astana Explores Emerging Trends and Risks

Source: astanatimes.com
Related Topics:
Gorod AstanaUnited StatesJudy KooYerkin TukumovJudy KuoSteven PinkerUnited States EmbassyQazaq Forum Judy KuoUs MissionMckinsey Global InstituteKazakhstan Institute For Strategic Studies KazQazaq ForumNew TechnologiesCentral AsiaKazakhstan InstituteStrategic StudiesDigital Forensic Research LabAtlantic Council Technology Programs